Clinical trial • Phase III • Cardiology
nurandociguat for Chronic kidney disease
Phase III trial of nurandociguat for Chronic kidney disease. 40 participants.
Overview
- Trial Therapeutic Area
- Cardiology
- Trial Disease
- Chronic kidney disease
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 16-01-2026
- First CTIS Authorization Date
- 09-03-2026
Trial design
Phase III trial across 1 site in Germany.
- Target Sample Size
- 40
Eligibility
Recruits 40 Vulnerable population selected; no further details on consent or assent handling are provided in the record..
- Vulnerable Population
- Vulnerable population selected; no further details on consent or assent handling are provided in the record.
Recruitment
- Planned Sample Size
- 40
- Recruitment Window Months
- 2
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 40
Germany
- Earliest CTIS Part Ii Submission Date
- 27-02-2026
- Latest Decision Or Authorization Date
- 09-03-2026
- Processing Time Days
- 10
- Number Of Sites
- 1
- Number Of Participants
- 40
Sites
- Site Name
- CRS Clinical Research Services Mannheim GmbH
- Department Name
- Clinical Research Services | Clinical Research Services Mannheim - Phase one unit
- Contact Person Name
- Edis Gasanin
- Contact Person Email
- edis.gasanin@crs-group.de
- Number Of Participants
- 40
Sponsor
Primary sponsor
- Full Name
- Bayer AG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- nurandociguat
Related trials
Other published trials that may interest you.